Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
-
Published:2019
Issue:
Volume:11
Page:46-50
-
ISSN:2213-0489
-
Container-title:Leukemia Research Reports
-
language:en
-
Short-container-title:Leukemia Research Reports
Author:
Alqasim Alauldeen Mudhafar ZubairORCID,
Obaid Ghasaq Mohsin,
Yaseen Yusra Ghaith,
Alwan Alaa Fadhil
Subject
Oncology,Hematology
Reference24 articles.
1. Cost effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012;Romero;Biomedica,2014
2. Jain P, Das V, Ranjan A, Chaudhary R and Pandey K. Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea. 2013 Oct; 2(4):156–61.
3. Chronic Myeloid Leukemia;Goldman,2011
4. Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report;Shimabukuro-Vornhagen;J. Med. Case Rep.,2011
5. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance;Kantarjian;Blood,2007
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献